Unresolved questions regarding the promise of the TPEx regimen - Authors' reply
- PMID: 34087138
- DOI: 10.1016/S1470-2045(21)00293-X
Unresolved questions regarding the promise of the TPEx regimen - Authors' reply
Conflict of interest statement
JG has received research grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS), Chugai, GlaxoSmithKline, Merck Serono, and Sanofi; and has been an advisory board member for AstraZeneca, BMS, Innate Pharma, and Merck, all outside the submitted work. AA has received grant support, paid to her institution, from the Groupe d'Oncologie Radiotherapie Tête et Cou (GORTEC; French Radiation and Oncology Group for Head and Neck) for the original study and has received grant support, paid to her institution, from F Hoffmann–La Roche, outside the submitted work. AF has received grant support, paid to his institution, from the GORTEC for the original study. UK has received grants and personal fees from Merck, outside the submitted work. JB participated in advisory boards for Merck Sharp & Dohme, BMS, Debiopharm, Merck, and AstraZeneca, outside the submitted work. RM has received research grants from Merck Serono and has been an advisory board member for AstraZeneca, BMS, Rakuten, Merck Serono, Merck Sharp & Dohme, Nanobiotics, Bayer, and Roche, all outside the submitted work.
Comment on
-
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
-
Unresolved questions regarding the promise of the TPEx regimen.Lancet Oncol. 2021 Jun;22(6):e227. doi: 10.1016/S1470-2045(21)00246-1. Lancet Oncol. 2021. PMID: 34087137 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
